Novel Pharmaceutical Dosage Form

Padiyar, A; Maheshwari, RK

doi:10.22270/jddt.v8i5.1901

Cited by 2 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…IR spectra are shown in fig. 2 and the interpretation of FT-IR spectrum peaks of diclofenac sodium is shown in Table 2 [16] . Differential Scanning Calorimetry (DSC) study of piroxicam drug sample: Pyris 6 DSC (Jade DSC) with thermal analyzer was used for the DSC investigation.…”

Section: Drug Characterizationmentioning

confidence: 99%

“…5 mg of drug diclofenac sodium was added and shaken vigorously for about 15-20 min on vortex. When a clear solution was formed then again the process was continued until turbidity appears [14][15][16][17][18][19][20][21][22][23][24] . The approximate solubility was noted in Table 5.…”

Section: Preformulation Studiesmentioning

confidence: 99%

“…Two blends were considered as they provide great solubility to diclofenac sodium for the formulation of injectable solution. As a result, these mixtures were chosen for further research [15,16] . These studies were conducted based on visual appearance, which included precipitation, crystal development and clarity.…”

Section: Preformulation Studiesmentioning

confidence: 99%

See 2 more Smart Citations

Formulation Development and In Vitro Evaluation of Diclofenac Sodium Injection for Pain Management

Padiyar,

Maheshwari

2024

IJPS

View full text Add to dashboard Cite

The current study aims to design, formulate, optimize and evaluate diclofenac sodium injection using a novel concept of solubilisation. The present formulation utilizes a mixed solvency concept for the development of an injectable dosage form of the sparingly water-soluble drug diclofenac sodium using solids as solubilizing compounds. Diclofenac sodium injection 75 mg/ml was formulated without using propylene glycol or any other liquid solubilize, hence can be injected through the intradeltoid route without any pain at the site of action. The developed formulation was evaluated for various parameters such as freeze-thaw study, viscosity, osmolality and physical, chemical and pH stability of formulations were studies. The outcomes of the study deciphered a successful formulation of diclofenac sodium injection using the mixed solvency concept.

show abstract

Section: Drug Characterizationmentioning

confidence: 99%

Section: Preformulation Studiesmentioning

confidence: 99%

See 1 more Smart Citation

Formulation Development and In Vitro Evaluation of Diclofenac Sodium Injection for Pain Management

Padiyar,

Maheshwari

2024

IJPS

View full text Add to dashboard Cite

show abstract

“…Many drugs that are poorly water-soluble have had their aqueous solubility improved by mixed hydrotropic solubilization. [4][5][6][7][8][9][10][11] Benefits of mixed hydrotropy…”

Section: Mixed Hydrotropymentioning

confidence: 99%

Untitled

2022

AJP

View full text Add to dashboard Cite

Background:The primary goal of this research is to investigate the concept of mixed solvency in terms of developing a large number of safe solvent systems for aqueous intramuscular injections that include water-soluble additives. As a result, pharmaceutical industries can use these solvent systems to provide intramuscular injections of drugs that are poorly water-soluble. Safe solubilizers' solubilizing properties can be utilised to improve the solubility of poorly water-soluble drugs. Objective: The main purpose of this research is to provide pharmaceutical manufacturers with novel approaches for aqueous IM injections. Materials and Methods: In the present study, we employed sodium benzoate, sodium acetate, sodium citrate, valine, l-lysine, arginine, ethanol, Tween 80 and benzoic acid as solubilizers and ornidazole, paracetamol, aspirin, salicylic acid, gatifloxacin, naproxen, meloxicam, furosemide, piroxicam, acyclovir, fenofibrate, indomethacin, norfloxacin, and nimesulide. Furosemide was selected as the drug for the formulation of a typical aqueous IM injectable solution. For the drug identification, melting ranges were determined all the drugs using melting point apparatus (Analab Scientific). UV identification was also done for all drugs using UV-visible spectrophotometer (Shimadzu 1700). The pH of blend was estimated using pH meter (Cyber Scan). Drug and excipient interference studies were performed before formulation using UV-visible spectrophotometer. Drug and excipient interference studies also done before the formulation. The composition of formulation is L-lysine (3% w/v), sodium acetate (10% w/v), arginine (10% w/v), and Tween 80 (5% w/v). Results: By the solubility studies in different blends, the possibility of some IM injection solution can prepare such as furosemide (20 mg/2 ml), piroxicam (20 mg/2 ml), repaglinide (16 mg/3 ml), indomethacin (25 mg/ml), and acyclovir (20 mg/3 ml) can be produced. Furosemide: Chemical, physical, and freeze thaw studies were performed for the stability study of formulation. The formulation gives satisfactory results during physical and chemical stability studies. The pH of formulation was also performed and it was found similar to the pH of blend (pH-7). Conclusion: From this research work, it is clear that mixed solvency concept can be employed to develop a large numbers of expectedly safe aqueous IM injection solution type aqueous solvent systems for poorly water-soluble drugs. Thus, solubilizing power of safe additives can be employed to make marketable aqueous IM injections.

show abstract

Novel Pharmaceutical Dosage Form

Cited by 2 publications

References 0 publications

Formulation Development and In Vitro Evaluation of Diclofenac Sodium Injection for Pain Management

Formulation Development and In Vitro Evaluation of Diclofenac Sodium Injection for Pain Management

Untitled

Contact Info

Product

Resources

About